Chromatin Remodeling of RasGRP3 Underlies Temozolomide Sensitivity in Glioblastoma Organoids
Year: 2026
Type: article
Abstract: Acquired resistance to temozolomide (TMZ) constitutes a formidable clinical barrier in the management of glioblastoma (GBM). GBM organoid models (GBO) that faithfully mirror the parental tumor phenotype serve as powerful research instruments to overcome the limitations in this field. We established GBOs derived from primary glioma patients and their TMZ low-sensitivity counterparts. To unravel the intricate molecular underpinnings of this process, we performed an unbiased, integrated multi-omics analysis encompassing epigenomic, 3D genomic, and transcriptomic profiling, coupled with dual CRISPR interference (CRISPRi) screening of TMZ-induced enhancers (TiEns) and their cognate target genes. Our findings demonstrate that enhancer-mediated 3D chromatin remodeling drives chemosensitivity predominantly by transcriptionally activating drug-sensitivity-associated genes, such as RasGRP3, VEGFA, BTN3A2, etc. Knockdown or knockout of these genes and enhancers renders glioma cells more sensitive to TMZ, especially RasGRP3. Our work unveils a druggable "enhancer-chromatin-target" signaling axis and proposes a novel combinatorial therapeutic strategy to surmount TMZ low sensitivity in GBM.
Source: Advanced Science
DOI: 10.1002/advs.78665
Authors: Bohan Chen, Guangsong Su, Yiting Huang, Rong Liu, Yingjie Song, Qian Xiao, Jie Lian, Chen Zhang, Yuhan Qiu, Qianlan Zhao, Jiayu Gu, Jian Zhong, Yixin Gao, Xujia Wu, Yiping Ma, Yaoqiang Zheng, Meng Zhang, Anshun He, Jinfang Bi, Peng Li, Zhongfang Zhao, Jiandang Shi, Lei Zhang, Bin Huang, Wange Lu, Nu Zhang
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,730
OpenAlex ID: W7235953879
